WHO Raises Warning Over Severe Scarcity of Obesity Injections
Less than one in 10 individuals eligible to benefit from obesity jabs like Wegovy are able to get them, caution the World Health Organization as it releases its initial recommendations on the drugs.
Considering over a billion people worldwide now classified as obese, it is advocating for increased and just access to this class of drugs.
Per estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The latest guidance recognises that obesity is a long-term condition that can be treated with thorough and continuous treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are major barriers to broad availability to the injections that can assist patients in reducing considerable body mass, notes the organization.
Skinny Jab Shortage
Even under the present most favorable scenario, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – less than 10% of the global need, according to the health organization.
The guideline calls on governments and firms to increase access, by approaches including patent sharing.
A patent on a key compound – the main component of a leading brand – is due to expire in several nations in 2026.
The Way Obesity Jabs Function
These medications mimick a natural hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so people reduce food intake.
Patients usually begin shedding pounds after several weeks of beginning the regular doses.
Evidence suggests patients may put most of the weight back on a year later of halting the drug, when their usual food cravings resume.
Being overweight or obese increases your risk for contracting diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight concerns people in all nations and was associated with 3.7 million deaths worldwide in 2024, according to the WHO.
